FIGURE 3.

Distributions of post‐NAC TILs and associations with pathological response and survival among patients with invasive residual breast tumor after NAC. (A) Distribution of post‐NAC TILs in all patients and the HR⁺HER2⁻, HER2⁺, and TNBC subgroups; (B) associations between post‐NAC TIL and Miller‐Payne grade after NAC; (C) disease‐free survival by post‐NAC TIL category; (D) overall survival by post‐NAC TIL category. HER2, human epidermal growth factor receptor 2; HR, hormonal receptor; NAC, neoadjuvant chemotherapy; TILs, tumor‐infiltrating lymphocytes; TNBC, triple‐negative breast cancer